Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.

McGivern U, Mitchell DM, McDowell C, O'Hare J, Corey G, O'Sullivan JM.

Clin Genitourin Cancer. 2012 Sep;10(3):190-5. doi: 10.1016/j.clgc.2012.04.003. Epub 2012 Jun 5.

PMID:
22677511
2.

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy.

Mitchell DM, McAleese J, Park RM, Stewart DP, Stranex S, Eakin RL, Houston RF, O'Sullivan JM.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1467-71. Epub 2007 Aug 8.

PMID:
17689886
3.

Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.

Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):529-33. doi: 10.1016/j.ijrobp.2013.02.004. Epub 2013 Mar 21.

PMID:
23523323
4.
5.

Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.

Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN.

Urol Int. 2005;75(3):217-21.

PMID:
16215308
6.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

7.

The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.

PMID:
22438406
9.

Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.

Petit JH, Gluck C, Kiger WS 3rd, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I.

Urol Oncol. 2008 Jul-Aug;26(4):372-7. doi: 10.1016/j.urolonc.2007.05.014. Epub 2008 Jan 8.

PMID:
18367113
10.

Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.

Akyol F, Selek U, Ozyigit G, Onal C, Akdogan B, Karabulut E, Ozen H.

J Natl Med Assoc. 2006 Jul;98(7):1058-61.

11.
12.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
13.

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ.

Urology. 2003 Jan;61(1):127-31.

PMID:
12559282
14.
15.

[The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].

Ouzaid I, RouprĂȘt M.

Prog Urol. 2011 Nov;21(12):866-74. doi: 10.1016/j.purol.2011.07.006. Epub 2011 Sep 16. French.

PMID:
22035913
17.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
18.

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.

PMID:
10223480
19.

Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.

Fair WR, Betancourt JE.

Mol Urol. 2000 Fall;4(3):241-8;discussion 249-50.

PMID:
11062380
20.

Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?

King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):341-7.

PMID:
15145146

Supplemental Content

Support Center